Clear Search

Showing 5 results for “skin”.

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study

Rheumatology (Oxford). 2022;61(6):2413–2423 doi: 10.1093/rheumatology/keab685

Proof-of-concept study for the safety and efficacy of filgotinib (FIL) and lanraplenib (LANRA) in cutaneous lupus (CLE) fails to meet primary endpoint, but select subgroups displayed a numerically greater treatment response to FIL relative to placebo.

Read more…

Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials

Lancet Rheumatol. Published online February 3, 2022

Across two pivotal phase 3 trials (TULIP-1 and TULIP-2), anifrolumab treatment improved systemic lupus erythematosus (SLE) disease activity across multiple organ domains, compared with placebo.

Read more…

Real-world Impact of Flaring on Patient-Reported Outcomes and Healthcare Resource Utilisation in Systemic Lupus Erythematosus

Clin Exp Rheumatol. 2021.Epub ahead of print

Data from the real world underscores the need for more effective strategies and treatments to alleviate or prevent flaring in systemic lupus erythematosus (SLE).

Despite data from Hong Kong and Canada showing an association of flaring with reduced health-related quality of life and increased healthcare resourse utilisation and costs, similar international data are limited.

Read more…

Treatment of refractory subacute cutaneous lupus erythematosus with baricitinib

Clin Exp Dermatol. 2021. Epub ahead of print

Phase II data and two individual case reports have shown significant improvement in signs and symptoms of disease in patients with systemic lupus erythematosus (SLE) receiving baricitinib. This case study by Joos et al. reports a further patient with SLE treated successfully with baricitinib.

Read more…